Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.
The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expenditure whilst ensuring universal coverage and rewarding innovation. These reforms include accelerating access to and granting average European prices for new innovative drugs, delisting drugs where there are concerns over their value and instigating rebates for excessive prescribing. Alongside this, ongoing initiatives to improve the quality and efficiency of prescribing include programmes to enhance generic prescribing and dispensing as well as to reduce antibacterial and anxiolytic/hypnotic prescribing. However, there have been few publications documenting the impact of specific reforms on the overall costs and quality of care, which have been exacerbated by compartmentalization of budgets. Estimates suggest savings of over 27 million euro/year by decreasing antibacterial prescribing, 450 million euro/year by not reimbursing ineffective drugs, 670 million euro/year from pharmaceutical company rebates and approximately 1 billion euro/year from increased prescribing and dispensing of generics (year 2003-7 values). Additional savings of at least 1.5 billion euro/year are seen as being possible from increased use of generics such as generic proton pump inhibitors, statins (HMG-CoA reductase inhibitors) and ACE inhibitors instead of current branded products such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]). Delisting drugs when there are concerns about their value provides an example to other countries with currently limited demand-side measures. Other possible examples include price : volume agreements and multifaceted campaigns to enhance generic prescribing and dispensing and reduce antibacterial prescribing. Possible future initiatives could include adopting more stringent criteria for categorizing new drugs as innovative as well as further reductions in the prices of generics. Other initiatives could include further enhancement of the quality and efficiency of prescribing, including formal auditing of physician prescribing, as well as increasing efforts to monitor the risk : benefit ratio of new drugs post-launch in real-world practice.
Sermet
Catherine
C
IRDES (Institut de recherche et de documentation en économie de la santé), Paris, France. Sermet@irdes.fr
Andrieu
Veronique
V
Godman
Brian
B
Van Ganse
Eric
E
Haycox
Alan
A
Reynier
Jean-Pierre
JP
D020811:Biomedical Technology / Q000191:economics* / Q000639:trends; D003363:Cost Control; D016527:Drug Costs / Q000639:trends*; D016568:Drugs, Generic / Q000191:economics / Q000592:standards; D005572:Formularies, Hospital as Topic / Q000592:standards; D005602:France; D018166:Health Care Reform / Q000191:economics* / Q000379:methods / Q000639:trends; D006801:Humans; D011785:Quality Assurance, Health Care / Q000191:economics* / Q000592:standards
D016568:Drugs, Generic